The Efficacy and Safety of PD-1PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
Joint Authors
Nie, Run-Cong
Zhao, Chong-Bang
Xia, Xiao-Wei
Luo, Ying-Shan
Wu, Ting
Zhou, Zhi-Wei
Yuan, Shu-Qiang
Wang, Yun
Li, Yuan-Fang
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-05-06
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Objectives.
To evaluate the efficacy of immuno-oncology combinational therapy (IOCT) versus monotherapy with programmed cell death 1 (PD-1) or PD-ligand 1 (PD-L1) inhibitors or conventional therapies, i.e., non-IOCT, in patients with advanced solid tumors.
Methods.
We systematically searched the PubMed, Embase, and Cochrane Library databases from January 2015 to October 2018 for eligible studies.
We included randomized trials of IOCT with available hazard ratios (HR) for death.
The random effects model was used to calculate pooled HR for death; heterogeneity was assessed using I2 statistics.
The main outcome measure was overall survival (OS).
Results.
After screening 483 relevant articles, we identified twelve trials comprising 5388 patients for quantitative analysis.
IOCT-treated patients had significantly higher tumor response rate (relative risk (RR): 2.51, 95% confidence interval (CI): 1.82-3.47), prolonged progression-free survival (HR 0.62, 95% CI: 0.53-0.74), and OS (HR 0.69, 95% CI: 0.61-0.78), compared with non-IOCT–treated patients.
Sensitivity analyses also demonstrated the OS advantage of IOCT across different combination modalities, intervention agents, malignancy types, and PD-L1 expression (all P<0.05).
Notably, there were higher odds of high-grade (grade≥3) adverse events with IOCT (RR: 1.81, 95% CI: 1.13-2.90), but the risk of treatment-related death (RR: 1.16, 95% CI: 0.84–1.60) was not increased compared with non-IOCT.
Conclusions.
IOCT is a preferable treatment option over PD-1/PD-L1 inhibitor monotherapy and conventional therapy for patients with advanced solid tumors.
However, we should note the increased incidence rate of high-grade AEs in IOCT.
American Psychological Association (APA)
Nie, Run-Cong& Zhao, Chong-Bang& Xia, Xiao-Wei& Luo, Ying-Shan& Wu, Ting& Zhou, Zhi-Wei…[et al.]. 2020. The Efficacy and Safety of PD-1PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. BioMed Research International،Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1134423
Modern Language Association (MLA)
Nie, Run-Cong…[et al.]. The Efficacy and Safety of PD-1PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. BioMed Research International No. 2020 (2020), pp.1-10.
https://search.emarefa.net/detail/BIM-1134423
American Medical Association (AMA)
Nie, Run-Cong& Zhao, Chong-Bang& Xia, Xiao-Wei& Luo, Ying-Shan& Wu, Ting& Zhou, Zhi-Wei…[et al.]. The Efficacy and Safety of PD-1PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1134423
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1134423